SEARCH:   Advanced

Blood, 15 February 2007, Vol. 109, No. 4, pp. 1653-1659. Prepublished online as a Blood First Edition Paper on October 31, 2006; DOI 10.1182/blood-2006-04-015537. This Article Full Text (PDF) All Versions of this Article: blood-2006-04-015537v1 109/4/1653    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Brown, M. Articles by Nicot, C. Search for Related Content PubMed PubMed Citation Articles by Brown, M. Articles by Nicot, C. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 7, 2006 Accepted September 29, 2006 Emodin and DHA potently increase arsenic trioxide interferon alpha induced cell death of HTLV-I transformed cells via generation of reactive oxygen species and inhibition of Akt and AP1 Megan Brown, Marcia Bellon, and Christophe Nicot* University of Kansas Medical Center, United States * Corresponding author; email: cnicot{at}kumc.edu. Adult T-cell leukemia (ATL) is an aggressive lymphoproliferative disease of poor clinical prognosis associated with infection by the human T-cell leukemia virus type I (HTLV-I). The use of arsenic trioxide (As2O3) has been shown to effectively treat acute promyelocytic leukemia (APL) with more than 80% of patients achieving complete remission. The combination of arsenic and interferon has also shown promising results in the treatment of ATL. The requirement for slow dosage increases of arsenic and the time required to achieve a pharmacological active dose in patients is a major obstacle since median survival of ATL patients is about 6 months. In this study we report a potent synergistic effect of the combination of arsenic trioxide and interferon alpha (As/IFN-) with emodin and DHA on cell cycle arrest and cell death of HTLV-I-infected cells. Importantly, we found that clinically achievable doses of DHA and Emodin allowed for reduced arsenic concentrations by 100 fold while still remaining highly toxic to tumor cells. Our data provide a rationale for combined use of As/IFN- with emodin and DHA in ATL patients refractory to conventional therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T.-C. Kuo, J.-S. Yang, M.-W. Lin, S.-C. Hsu, J.-J. Lin, H.-J. Lin, T.-C. Hsia, C.-L. Liao, M.-D. Yang, M.-J. Fan, et al. Emodin Has Cytotoxic and Protective Effects in Rat C6 Glioma Cells: Roles of Mdr1a and Nuclear Factor {kappa}B in Cell Survival J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 736 - 744. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020